Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1880-1887

  Maurer, Britta ^a   Distler, Alfiya ^b   Suliman, Yossra A ^c   Gay, Renate E ^a   Michel, Beat A ^a   Gay, Steffen ^a   Distler, Jörg H W ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; BIOSYNTHESIS; CELL CULTURE; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; VASCULARIZATION;

ANIMALS; BLEOMYCIN; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FIBROBLASTS; FIBROSIS; MALE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; SCLERODERMA, SYSTEMIC; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882464963     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203535     Document Type: Article

References (38)

1. Guiducci S, Distler O, Distler JH, et al. Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology (Oxford) 2008;47(Suppl 5):v18-20.
2. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007;9(2):S3.
3. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102-3.
4. Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:1939-47.
5. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 1995;92:7657-61.
6. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001;158:1145-60.
7. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
8. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
9. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998;111:1-6.
10. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
11. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311-22.
12. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500.
13. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
14. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 1976;82:493-512.
15. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-34.
16. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.
17. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43.
18. Lee TH, Avraham H, Lee SH, et al. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002;277:10445-51.
19. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-7.
20. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-85.
21. Ou XM, Li WC, Liu DS, et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 2009;9:70-9.
22. Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003;52:1347-54.
23. Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005;175:1224-31.
24. Lin SL, Chang FC, Schrimpf C, et al. Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011;178:911-23.
25. Karvinen H, Pasanen E, Rissanen TT, et al. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther 2011;18:1166-72.
26. Gay S, Jones RE Jr., Huang GQ, et al. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989;92:301-3.
27. Klareskog L, Gustafsson R, Scheynius A, et al. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990;33:1534-41.
28. Yamakage A, Kikuchi K, Smith EA, et al. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992;175:1227-34.
29. Ludwicka A, Ohba T, Trojanowska M, et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995M; 22:1876-83.
30. Joukov V, Kaipainen A, Jeltsch M, et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 1997;173:211-15.
31. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60.
32. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology 2008;4755:v2-4.
33. Liu N, Guo JK, Pang M, et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol 2012;23:854-67.
34. Yamane K, Ihn H, Tamaki K. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum 2003;48:1652-66.
35. Lee KS, Park SJ, Kim SR, et al. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 2008;31:523-31.
36. Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest 2008;88:579-90.
37. Manetti M, Guiducci S, Ibba-Manneschi L, et al. Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF (165) b splice variant. Trends Cardiovasc Med 2011;21:204-10.
38. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-27.